According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.79306. At the end of 2023 the company had a P/S ratio of 5.89.
Year | P/S ratio | Change |
---|---|---|
2023 | 5.89 | -49.48% |
2022 | 11.7 | -8.73% |
2021 | 12.8 | -40.81% |
2020 | 21.6 | 74.46% |
2019 | 12.4 | -11.3% |
2018 | 13.9 | 53.06% |
2017 | 9.11 | 4.45% |
2016 | 8.72 | -46.96% |
2015 | 16.4 | 2.11% |
2014 | 16.1 | -48.6% |
2013 | 31.3 | 75.34% |
2012 | 17.9 | 1.63% |
2011 | 17.6 | -69.93% |
2010 | 58.5 | 48.53% |
2009 | 39.4 | -24.36% |
2008 | 52.0 | -64.3% |
2007 | 146 | -74.13% |
2006 | 564 | -33.42% |
2005 | 847 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.78 | -34.83% | ๐บ๐ธ USA |
Pfizer PFE | 2.46 | -57.57% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.8 | 258.77% | ๐บ๐ธ USA |
Sanofi SNY | 2.25 | -61.16% | ๐ซ๐ท France |
Baxter BAX | 1.35 | -76.68% | ๐บ๐ธ USA |
MannKind Corp MNKD | 5.55 | -4.15% | ๐บ๐ธ USA |